Kornitzer Capital Management Inc. KS Makes New Investment in Repligen Corporation $RGEN

Kornitzer Capital Management Inc. KS acquired a new stake in Repligen Corporation (NASDAQ:RGEN) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 78,280 shares of the biotechnology company’s stock, valued at approximately $10,464,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Rhenman & Partners Asset Management AB grew its position in Repligen by 333.3% during the second quarter. Rhenman & Partners Asset Management AB now owns 19,500 shares of the biotechnology company’s stock valued at $2,425,000 after purchasing an additional 15,000 shares in the last quarter. XTX Topco Ltd grew its holdings in shares of Repligen by 34.1% during the 2nd quarter. XTX Topco Ltd now owns 17,352 shares of the biotechnology company’s stock valued at $2,158,000 after acquiring an additional 4,417 shares in the last quarter. Delta Investment Management LLC acquired a new position in shares of Repligen in the third quarter worth $6,779,000. Congress Asset Management Co. boosted its position in Repligen by 43.4% during the third quarter. Congress Asset Management Co. now owns 218,592 shares of the biotechnology company’s stock valued at $29,219,000 after purchasing an additional 66,142 shares during the last quarter. Finally, Blue Whale Capital LLP purchased a new position in Repligen in the second quarter valued at about $35,782,000. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Up 0.6%

Shares of RGEN opened at $163.34 on Tuesday. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $182.52. The stock has a market cap of $9.19 billion, a price-to-earnings ratio of 8,171.09, a P/E/G ratio of 2.94 and a beta of 1.12. The company has a 50-day moving average price of $164.28 and a two-hundred day moving average price of $143.25. The company has a quick ratio of 7.14, a current ratio of 8.36 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 EPS for the quarter, topping the consensus estimate of $0.42 by $0.04. Repligen had a return on equity of 4.66% and a net margin of 0.25%.The business had revenue of $188.81 million during the quarter, compared to the consensus estimate of $181.23 million. During the same quarter last year, the company earned $0.43 EPS. Repligen’s revenue was up 21.9% on a year-over-year basis. Equities analysts predict that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on RGEN. UBS Group raised their price target on Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Barclays boosted their target price on shares of Repligen from $175.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Canaccord Genuity Group raised their price target on shares of Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a research report on Wednesday, October 29th. Finally, Weiss Ratings raised shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $179.62.

Insider Transactions at Repligen

In related news, COO James Bylund sold 2,191 shares of Repligen stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total value of $331,301.11. Following the completion of the transaction, the chief operating officer directly owned 21,520 shares of the company’s stock, valued at $3,254,039.20. The trade was a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Anthony Hunt sold 20,000 shares of the stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $154.61, for a total transaction of $3,092,200.00. Following the sale, the director directly owned 80,743 shares in the company, valued at approximately $12,483,675.23. This represents a 19.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 49,657 shares of company stock valued at $7,721,077. Corporate insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.